scholarly journals Real-World Treatment Patterns and Outcomes Among Multiple Myeloma Patients with Asthma and COPD in the United States

2021 ◽  
Author(s):  
Megan S. Rice ◽  
Sarah Naeger ◽  
Erin Singh
Keyword(s):  
United States ◽  
Multiple Myeloma ◽  
Real World ◽  
The United States ◽  
Treatment Patterns

P168 Real-world characteristics and treatment patterns in urticaria patients initiating omalizumab in the United States

2017 ◽  
Vol 119 (5) ◽  
pp. S44
Author(s):  
L. Wang ◽  
A. Kavati ◽  
X. Ke ◽  
D. Wertz ◽  
Q. Huang ◽  
...  
Keyword(s):  
United States ◽  
Real World ◽  
The United States ◽  
Treatment Patterns

Real-world treatment patterns and outcomes of triple-exposed multiple myeloma patients treated in community oncology practices in the United States.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18727-e18727
Author(s):  
Robert Smith ◽  
Mei Xue ◽  
Natalie Dorrow ◽  
Prateesh Varughese ◽  
Cosima Hogea ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Real World ◽  
Proteasome Inhibitors ◽  
Office Visit ◽  
The United States ◽  
Subsequent Treatment ◽  
Treatment Patterns ◽  
Duration Of Therapy ◽  
The Us

e18727 Background: Treatment for multiple myeloma (MM) over the past decade has significantly improved survival. In particular, 3 drug classes have altered the treatment paradigm for MM patients: proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies (anti-CD38s). Despite these advances, the majority of patients with MM will become refractory to PIs, IMiDs, and anti-CD38s, and limited evidence indicates these patients have poor outcomes. A retrospective study in the US showed that 275 patients treated at 14 academic institutions with prior exposure to a PI, IMiD, and anti-CD38 had median overall survival of 9.2 months. The aim of this study was to evaluate real-world treatment patterns and outcomes (duration of therapy and overall survival) of patients who had been treated with a PI, IMiD, and anti-CD38 in community practices in the US. Methods: This retrospective observational study was conducted using the Integra Connect (IC) database. The IC database includes electronic health data from structured and unstructured fields from 12 community practices on the East and West Coast of the US. Adult patients with ≥2 ICD-9/ICD-10 codes for MM on at least 2 separate dates, who received MM treatment between Jan 1, 2016, and Dec 31, 2019, with treatment history that included at least one PI, one IMiD, and one anti-CD38 (triple exposed), and initiated a subsequent line of therapy (s-LOT) after becoming triple exposed, were included. Duration of length of s-LOT was defined as number of days from start of s-LOT to last-day supply of s-LOT. Overall survival was defined as the length of time from start of s-LOT through death or the date of the last office visit. Results: A total of 501 patients were included in this analysis. The median age of patients was 64.9 years; 50% were male; 50% had commercial insurance. 82.8% of patients had ECOG 0 or 1 at diagnosis and had received a median of 3 prior lines of therapy (LOTs) before initiating s-LOT. Prior to initiating s-LOT, 91% had been exposed to bortezomib, 81% to carfilzomib, 94% to lenalidomide, 82% to pomalidomide, and 100% to daratumumab. In s-LOT, 95% received treatment that included same drug or same drug class (30% received bortezomib, 48% carfilzomib, 31% lenalidomide, 47% pomalidomide, and 31% daratumumab). The median duration of s-LOT was 78 days and median survival was 10.3 months (308 days) from initiation of s-LOT. Conclusions: For triple-class exposed patients, there is a lack of consensus on the most efficacious approach to subsequent treatment. The present study shows a significant amount of retreatment with previously used agents or classes among these patients with short duration of therapy and poor survival. As has been previously noted, new strategies and agents targeting novel aspects of MM are needed to improve outcomes for these patients. Disclosures: This study (213286) was sponsored by GlaxoSmithKline.

scholarly journals Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey

2019 ◽  
Vol 35 (5) ◽  
pp. 927-935 ◽  
Author(s):  
Bruno C. Medeiros ◽  
Bhavik J. Pandya ◽  
Anna Hadfield ◽  
James Pike ◽  
Samuel Wilson ◽  
...  
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Real World ◽  
Myeloid Leukemia ◽  
The United States ◽  
Treatment Patterns ◽  
Cross Sectional ◽  
World Survey ◽  
Acute Myeloid

Treatment Patterns From 2009-2015 in Patients With Newly Diagnosed Multiple Myeloma in the United States: A Report From the Connect® MM Registry

2017 ◽  
Vol 17 (1) ◽  
pp. e20-e21 ◽  
Author(s):  
Robert Rifkin ◽  
Rafat Abonour ◽  
Brian Durie ◽  
Cristina Gasparetto ◽  
Sundar Jagannath ◽  
...  
Keyword(s):  
United States ◽  
Multiple Myeloma ◽  
The United States ◽  
Treatment Patterns ◽  
Newly Diagnosed

scholarly journals PF321 REAL-WORLD TREATMENT PATTERNS OF PATIENTS DIAGNOSED WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE UNITED STATES (US)

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 113
Author(s):  
X. Yang ◽  
F. Laliberté ◽  
G. Germain ◽  
M. Raut ◽  
M.S. Duh ◽  
...  
Keyword(s):  
United States ◽  
B Cell ◽  
Real World ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
The United States ◽  
Treatment Patterns ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data

2019 ◽  
Vol 14 ◽  
pp. 100215 ◽  
Author(s):  
Christopher Kim ◽  
Sumita Bhatta ◽  
Lori Cyprien ◽  
Rafael Fonseca ◽  
Rohini K. Hernandez
Keyword(s):  
United States ◽  
Multiple Myeloma ◽  
Real World ◽  
The United States ◽  
Real World Data ◽  
World Data ◽  
Skeletal Related Events
Sign in / Sign up

Export Citation Format

Share Document